Literature DB >> 39584

Haemodynamic effects of a new beta 1-receptor agonist in acute myocardial infarction. A useful antidote to unwanted cardiac effects of beta-blocking agents.

R Ariniego, F Waagstein, B Mombay, A Hjalmarson.   

Abstract

The haemodynamic effects of a new beta 1-receptor agonist, 1-(4 hydroxyphenoxy) 3-isopropylamino-2-propanol, were studied in 25 patients after acute myocardial infarction using non-invasive methods. The drug caused an increase in systolic blood pressure and pulse pressure, without change in diastolic blood pressure, and a slight increase in heart rate and reduction in the pre-ejection period. These changes were greater in patients without a history of left heart failure. It is suggested that this cardioselective drug possesses positive inotropic activity but only slight positive chronotropic activity. The substance has been further investigated as a possible antidote to unwanted cardiac side effects of the cardioselective beta-blocker, metoprolol. The changes in the cardiovascular dynamics caused by metoprolol in patients with acute myocardial infarction were promptly reversed by this new beta 1-agonist. With its positive inotropic properties and its efficacy in reversing the effects of a cardioselective beta-blocker, the drug is a potentially useful pharmacological agent to support an acutely depressed myocardium in patients on beta-blocking agents.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 39584      PMCID: PMC482127          DOI: 10.1136/hrt.42.2.139

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  29 in total

1.  Clinical experience with use of ultrasound sphygmomanometer.

Authors:  C F George; P J Lewis; A Petrie
Journal:  Br Heart J       Date:  1975-08

2.  Accuracy of the stroke index as determined by the transthoracic electrical impedance method.

Authors:  C Z Naggar; D B Dobnik; A P Flessas; B J Kripke; T J Ryan
Journal:  Anesthesiology       Date:  1975-02       Impact factor: 7.892

3.  Plasma norepinephrine in congestive heart failure.

Authors:  J A Thomas; B H Marks
Journal:  Am J Cardiol       Date:  1978-02       Impact factor: 2.778

4.  Human pharmacology studies with a new, orally active stimulant of cardiac adrenergic beta-receptors.

Authors:  M Knaus; B Pfister; U C Dubach; P R Imhof
Journal:  Am Heart J       Date:  1978-05       Impact factor: 4.749

5.  Double-blind study of the effect of cardioselective beta-blockade on chest pain in acute myocardial infarction.

Authors:  F Waagstein; A C Hjalmarson
Journal:  Acta Med Scand Suppl       Date:  1976

6.  Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists.

Authors:  E Carlsson; C G Dahlöf; A Hedberg; H Persson; B Tångstrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

7.  Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy.

Authors:  R R Miller; H G Olson; E A Amsterdam; D T Mason
Journal:  N Engl J Med       Date:  1975-08-28       Impact factor: 91.245

8.  Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man.

Authors:  O Rönn; C Graffner; G Johnsson; L Jordö; P Lundborg; J Wikstrand
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

9.  Hemodynamic effect of dobutamine in patients with severe heart failure.

Authors:  N Akhtar; E Mikulic; J N Cohn; M H Chaudhry
Journal:  Am J Cardiol       Date:  1975-08       Impact factor: 2.778

10.  The use of dobutamine in myocardial infarction for reversal of the cardiodepressive effect of metoprolol.

Authors:  F Waagstein; I Malek; A C Hjalmarson
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

View more
  14 in total

1.  Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Br Heart J       Date:  1980-08

2.  Haemodynamic effects, plasma concentrations and tolerance of orally administered prenalterol in man.

Authors:  A Weiss; B Pfister; P Imhof; P H Degen; D Burckhardt; U C Dubach
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

3.  Amrinone--promising innovation for treatment of the failing heart.

Authors:  R Hayward
Journal:  Intensive Care Med       Date:  1983       Impact factor: 17.440

4.  Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.

Authors:  A C Tweddel; R G Murray; D Pearson; W Martin; I Hutton
Journal:  Br Heart J       Date:  1982-04

5.  Cardiostimulatory effects of prenalterol, a beta-1 adrenoceptor partial agonist, in vivo and in vitro. Correlation between physiological effects and adenylate cyclase activity.

Authors:  A Hedberg; E Carlsson; E Fellenius; B Lundgren
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-02       Impact factor: 3.000

6.  Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.

Authors:  H Drexler; H Löllgen; H Just
Journal:  Klin Wochenschr       Date:  1981-06-15

7.  Influence of heart rate on the effects of prenalterol on regional myocardial blood flow and function during coronary stenosis in dogs.

Authors:  A Berdeaux; C Bonhenry; P Duhazé; J F Giudicelli; C Thuillez
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

8.  Effects of prenalterol on cardiac performance and transmural myocardial perfusion in patients with chronic renal failure.

Authors:  T Pedersen; K Cleemann-Rasmussen; I Brynjolf; H Ording; P E Nielsen; K Rasmussen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  The effects of intravenous prenalterol on ventricular performance, as assessed by radionuclide ventriculography, in patients with ischaemic heart disease.

Authors:  A L Muir; W J Hannan; N G Dewhurst; I M Slessor
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

10.  beta 1-and beta 2-adrenoceptor stimulatory effects of prenalterol.

Authors:  H Mattsson; T Andersson; E Carlsson; A Hedberg; B Lundgren; T Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.